Market closedNon-fractional
Myriad Genetics/MYGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Myriad Genetics
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Ticker
MYGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Salt Lake City, United States
Employees
2,700
Website
www.myriad.com
Myriad Genetics Metrics
BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$2.77
EPS
1.96
Beta
-
Dividend rate
Price and volume
Market cap
$2.5B
Beta
1.96
Financial strength
Current ratio
1.987
Quick ratio
1.522
Long term debt to equity
17.5
Total debt to equity
19.316
Interest coverage (TTM)
-39.41%
Management effectiveness
Return on assets (TTM)
-6.27%
Return on equity (TTM)
-29.41%
Valuation
Price to revenue (TTM)
3.056
Price to book
3.3
Price to tangible book (TTM)
18.98
Price to free cash flow (TTM)
-15.293
Growth
Revenue change (TTM)
11.44%
Earnings per share change (TTM)
53.01%
3-year revenue growth (CAGR)
11.00%
3-year earnings per share growth (CAGR)
11.98%
What the Analysts think about Myriad Genetics
Analyst Ratings
Majority rating from 12 analysts.
Myriad Genetics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$202M
2.85%
Net income
-$26M
-16.67%
Profit margin
-12.85%
-18.98%
Myriad Genetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.03
$0.04
-$0.01
-
Expected
-$0.09
-$0.08
$0.01
-$0.10
-$0.01
Surprise
-5.88%
-63.01%
214.29%
-90.47%
-
Myriad Genetics News
AllArticlesVideos
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
GlobeNewsWire·2 weeks ago
Myriad Genetics Earns 2024 Great Place To Work® Certification™
GlobeNewsWire·3 weeks ago
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Myriad Genetics stock?
Myriad Genetics (MYGN) has a market cap of $2.5B as of July 27, 2024.
What is the P/E ratio for Myriad Genetics stock?
The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of July 27, 2024.
Does Myriad Genetics stock pay dividends?
No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Myriad Genetics dividend payment date?
Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Myriad Genetics?
Myriad Genetics (MYGN) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Myriad Genetics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.